View article

Background. Managing recurrent C. difficile infection (CDI) is challenging due to the limited effectiveness of current treatment options. Fecal transplant (FT) appears to be an effective mechanism for managing multiply recurrent CDI. Studies have looked at the acceptability of FT. However, little is known about the patients who seek FT for recurrent CDI. We report the demographics of subjects enrolled in an ongoing Phase 2 study (PUNCH CD) of RBX2660 (microbiota suspension), a next generation standardized and commercially prepared version of FT for the treatment of recurrent CDI.

Methods. The PUNCH CD study enrolled a range of patients with recurrent CDI who were:≥ 18 years with recurrent CDI who had at least two recurrences after a primary episode and completed at least two rounds of standard-of-care oral antibiotic therapy or had at least two episodes of severe CDI resulting in hospitalization.

Results …